Alireza Partoazar, Ramin Goudarzi, Ahmad Reza Dehpour
{"title":"治疗性脂质体与活性分子协同作用,增强靶向治疗。","authors":"Alireza Partoazar, Ramin Goudarzi, Ahmad Reza Dehpour","doi":"10.1080/1061186X.2025.2533336","DOIUrl":null,"url":null,"abstract":"<p><p>Liposomes composed of phospholipids (PLs) either alone or with an active molecule, can reveal a significant potential in the improvement of severe disorders such as Alzheimer's disease, osteoporosis, and inflammatory conditions. For instance, PLs exhibit anti-inflammatory, antioxidant, neuroprotective, and osteogenic properties in pathological conditions which accelerate the therapeutic effect of the drugs. These pharmacological properties can be modulated by the type and dose of PLs or liposome administration. They affect disorders through the signalling pathways, down or upregulation of gene expression, balance of oxidative stress, and other biological mechanisms. Interestingly, liposomes containing essential PLs like phosphatidylserine with active molecules such as curcumin or alendronate could synergistically improve certain diseases like osteoporosis in experimental models. Accordingly, we aimed to highlight the unique advantages of various PLs or liposomes with an emphasis on their diverse therapeutic modalities and potentiation of liposomes in synergy with the cargos in experimental studies. These properties suggest a promising approach to enhance drug efficacy and mitigate the side effects through reduced drug usage in chronic diseases, however, their clinical translation requires further validation of safety and effectiveness in human.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-9"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapeutic liposomes synergize with active molecules to enhance targeted therapy.\",\"authors\":\"Alireza Partoazar, Ramin Goudarzi, Ahmad Reza Dehpour\",\"doi\":\"10.1080/1061186X.2025.2533336\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Liposomes composed of phospholipids (PLs) either alone or with an active molecule, can reveal a significant potential in the improvement of severe disorders such as Alzheimer's disease, osteoporosis, and inflammatory conditions. For instance, PLs exhibit anti-inflammatory, antioxidant, neuroprotective, and osteogenic properties in pathological conditions which accelerate the therapeutic effect of the drugs. These pharmacological properties can be modulated by the type and dose of PLs or liposome administration. They affect disorders through the signalling pathways, down or upregulation of gene expression, balance of oxidative stress, and other biological mechanisms. Interestingly, liposomes containing essential PLs like phosphatidylserine with active molecules such as curcumin or alendronate could synergistically improve certain diseases like osteoporosis in experimental models. Accordingly, we aimed to highlight the unique advantages of various PLs or liposomes with an emphasis on their diverse therapeutic modalities and potentiation of liposomes in synergy with the cargos in experimental studies. These properties suggest a promising approach to enhance drug efficacy and mitigate the side effects through reduced drug usage in chronic diseases, however, their clinical translation requires further validation of safety and effectiveness in human.</p>\",\"PeriodicalId\":15573,\"journal\":{\"name\":\"Journal of Drug Targeting\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drug Targeting\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1061186X.2025.2533336\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Targeting","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1061186X.2025.2533336","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Therapeutic liposomes synergize with active molecules to enhance targeted therapy.
Liposomes composed of phospholipids (PLs) either alone or with an active molecule, can reveal a significant potential in the improvement of severe disorders such as Alzheimer's disease, osteoporosis, and inflammatory conditions. For instance, PLs exhibit anti-inflammatory, antioxidant, neuroprotective, and osteogenic properties in pathological conditions which accelerate the therapeutic effect of the drugs. These pharmacological properties can be modulated by the type and dose of PLs or liposome administration. They affect disorders through the signalling pathways, down or upregulation of gene expression, balance of oxidative stress, and other biological mechanisms. Interestingly, liposomes containing essential PLs like phosphatidylserine with active molecules such as curcumin or alendronate could synergistically improve certain diseases like osteoporosis in experimental models. Accordingly, we aimed to highlight the unique advantages of various PLs or liposomes with an emphasis on their diverse therapeutic modalities and potentiation of liposomes in synergy with the cargos in experimental studies. These properties suggest a promising approach to enhance drug efficacy and mitigate the side effects through reduced drug usage in chronic diseases, however, their clinical translation requires further validation of safety and effectiveness in human.
期刊介绍:
Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs.
Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.